OBJECTIVE: The aim of the study was to define chronic HBV phenotypes in a large, cohort of United States and Canadian children utilizing recently published population-based upper limit of normal alanine aminotransferase levels (ULN ALT), compared with local laboratory ULN; identify relationships with host and viral factors. BACKGROUND: Chronic hepatitis B virus (HBV) infection has been characterized by phases or phenotypes, possibly associated with prognosis and indications for therapy. METHODS: Baseline enrollment data of children in the Hepatitis B Research Network were examined. Phenotype definitions were inactive carrier: HBeAg-negative with low HBV DNA and normal ALT levels; immune-tolerant: HBeAg-positive with high HBV DNA but normal ALT levels; or chronic hepatitis B: HBeAg-positive or -negative with high HBV DNA and abnormal ALT levels. RESULTS: Three hundred seventy-one participants were analyzed of whom 274 were HBeAg-positive (74%). Younger participants were more likely be HBeAg-positive with higher HBV DNA levels. If local laboratory ULN ALT levels were used, 35% were assigned the immune tolerant phenotype, but if updated ULN were applied, only 12% could be so defined, and the remaining 82% would be considered to have chronic hepatitis B. Among HBeAg-negative participants, only 21 (22%) were defined as inactive carriers and 14 (14%) as HBeAg-negative chronic hepatitis B; the majority (61%) had abnormal ALT and low levels of HBV DNA, thus having an indeterminant phenotype. Increasing age was associated with smaller proportions of HBeAg-positive infection. CONCLUSIONS: Among children with chronic HBV infection living in North America, the immune tolerant phenotype is uncommon and HBeAg positivity decreases with age.
OBJECTIVE: The aim of the study was to define chronic HBV phenotypes in a large, cohort of United States and Canadian children utilizing recently published population-based upper limit of normal alanine aminotransferase levels (ULN ALT), compared with local laboratory ULN; identify relationships with host and viral factors. BACKGROUND:Chronic hepatitis B virus (HBV) infection has been characterized by phases or phenotypes, possibly associated with prognosis and indications for therapy. METHODS: Baseline enrollment data of children in the Hepatitis B Research Network were examined. Phenotype definitions were inactive carrier: HBeAg-negative with low HBV DNA and normal ALT levels; immune-tolerant: HBeAg-positive with high HBV DNA but normal ALT levels; or chronic hepatitis B: HBeAg-positive or -negative with high HBV DNA and abnormal ALT levels. RESULTS: Three hundred seventy-one participants were analyzed of whom 274 were HBeAg-positive (74%). Younger participants were more likely be HBeAg-positive with higher HBV DNA levels. If local laboratory ULN ALT levels were used, 35% were assigned the immune tolerant phenotype, but if updated ULN were applied, only 12% could be so defined, and the remaining 82% would be considered to have chronic hepatitis B. Among HBeAg-negative participants, only 21 (22%) were defined as inactive carriers and 14 (14%) as HBeAg-negative chronic hepatitis B; the majority (61%) had abnormal ALT and low levels of HBV DNA, thus having an indeterminant phenotype. Increasing age was associated with smaller proportions of HBeAg-positive infection. CONCLUSIONS: Among children with chronic HBV infection living in North America, the immune tolerant phenotype is uncommon and HBeAg positivity decreases with age.
Authors: David A Colantonio; Lianna Kyriakopoulou; Man Khun Chan; Caitlin H Daly; Davor Brinc; Allison A Venner; Maria D Pasic; David Armbruster; Khosrow Adeli Journal: Clin Chem Date: 2012-02-27 Impact factor: 8.327
Authors: Maureen M Jonas; Deirdre A Kelley; Jacek Mizerski; Isabel B Badia; Jorge A Areias; Kathleen B Schwarz; Nancy R Little; Martin J Greensmith; Stephen D Gardner; M Steve Bell; Etienne M Sokal Journal: N Engl J Med Date: 2002-05-30 Impact factor: 91.245
Authors: Philip Rosenthal; Simon C Ling; Steven H Belle; Karen F Murray; Norberto Rodriguez-Baez; Sarah J Schwarzenberg; Jeffrey Teckman; Hsing-Hua S Lin; Kathleen B Schwarz Journal: Hepatology Date: 2019-02-20 Impact factor: 17.425
Authors: A M Di Bisceglie; M Lombardero; J Teckman; L Roberts; H L A Janssen; S H Belle; J H Hoofnagle Journal: J Viral Hepat Date: 2016-12-05 Impact factor: 3.728
Authors: Norah A Terrault; Abdus S Wahed; Jordan J Feld; Stewart L Cooper; Mark G Ghany; Mauricio Lisker-Melman; Robert Perrillo; Richard K Sterling; Mandana Khalili; Raymond T Chung; Philip Rosenthal; Robert J Fontana; Arif Sarowar; Daryl T Y Lau; Junyao Wang; Anna S Lok; Harry L A Janssen Journal: Hepatology Date: 2022-01-26 Impact factor: 17.425
Authors: Daniel Traum; Yue J Wang; Kathleen B Schwarz; Jonathan Schug; David Kh Wong; Harry LA Janssen; Norah A Terrault; Mandana Khalili; Abdus S Wahed; Karen F Murray; Phillip Rosenthal; Simon C Ling; Norberto Rodriguez-Baez; Richard K Sterling; Daryl Ty Lau; Timothy M Block; Michael D Feldman; Elizabeth E Furth; William M Lee; David E Kleiner; Anna S Lok; Klaus H Kaestner; Kyong-Mi Chang Journal: JCI Insight Date: 2021-04-08
Authors: Simon C Ling; Hsing-Hua S Lin; Karen F Murray; Philip Rosenthal; Douglas Mogul; Norberto Rodriguez-Baez; Sarah Jane Schwarzenberg; Jeffrey Teckman; Kathleen B Schwarz Journal: J Pediatr Date: 2021-05-20 Impact factor: 6.314
Authors: Emanuele Nicastro; Lorenzo Norsa; Angelo Di Giorgio; Giuseppe Indolfi; Lorenzo D'Antiga Journal: World J Gastroenterol Date: 2021-05-28 Impact factor: 5.742